Absci (ABSI) versus Its Rivals Financial Comparison
Absci (NASDAQ:ABSI – Get Rating) is one of 40 public companies in the “Commercial physical research” industry, but how does it compare to its rivals? We will compare Absci to related businesses based on the strength of its analyst recommendations, risk, profitability, earnings, valuation, dividends and institutional ownership.
Institutional and Insider Ownership
40.0% of Absci shares are held by institutional investors. Comparatively, 59.5% of shares of all “Commercial physical research” companies are held by institutional investors. 11.4% of shares of all “Commercial physical research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
profitability
This table compares Absci and its rivals’ net margins, return on equity and return on assets.
| net margins | return on equity | return on assets | |
| absci | -2,633.14% | -36.19% | -22.99% |
| Absci Competitors | -260.35% | -8.17% | -2.92% |
Earnings and Valuation
This table compares Absci and its rivals gross revenue, earnings per share and valuation.
| Gross revenue | Net Income | Price/earnings ratio | |
| absci | $4.78 million | -$100.96 million | -1.06 |
| Absci Competitors | $2.80 billion | $97.54 million | 13.39 |
Absci’s rivals have higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Absci and its rivals, as reported by MarketBeat.
| sell ratings | hold ratings | Buy rating | Strong Buy Ratings | rating score | |
| absci | 1 | 3 | 3 | 0 | 2.29 |
| Absci Competitors | 105 | 774 | 1307 | 30 | 2.57 |
Absci currently has a consensus price target of $20.40, indicating a potential upside of 479.55%. As a group, “Commercial physical research” companies have a potential upside of 45.27%. Given Absci’s higher probable upside, equities analysts clearly believe Absci is more favorable than its rivals.
Summary
Absci rivals beat Absci on 10 of the 11 factors compared.
About Absci (Get Rating)
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Receive News & Ratings for Absci Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Absci and related companies with MarketBeat.com’s FREE daily email newsletter.